Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Review, H1 2015

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Review, H1 2015', provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 6

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 7

Therapeutics Development 8

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Therapeutics under Development by Companies 10

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Therapeutics under Investigation by Universities/Institutes 17

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline Products Glance 21

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Products under Development by Companies 25

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Products under Investigation by Universities/Institutes 32

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Companies Involved in Therapeutics Development 35

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Therapeutics Assessment 108

Drug Profiles 119

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Recent Pipeline Updates 292

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects 340

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Discontinued Products 347

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Product Development Milestones 348

Appendix 355

List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2015 24

Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Comparative Analysis, H1 2015 25

Number of Products under Development by Companies, H1 2015 27

Number of Products under Development by Companies, H1 2015 (Contd..1) 28

Number of Products under Development by Companies, H1 2015 (Contd..2) 29

Number of Products under Development by Companies, H1 2015 (Contd..3) 30

Number of Products under Development by Companies, H1 2015 (Contd..4) 31

Number of Products under Development by Companies, H1 2015 (Contd..5) 32

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 35

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 36

Comparative Analysis by Late Stage Development, H1 2015 37

Comparative Analysis by Clinical Stage Development, H1 2015 38

Comparative Analysis by Early Stage Development, H1 2015 39

Comparative Analysis by Unknown Stage Development, H1 2015 40

Products under Development by Companies, H1 2015 41

Products under Development by Companies, H1 2015 (Contd..1) 42

Products under Development by Companies, H1 2015 (Contd..2) 43

Products under Development by Companies, H1 2015 (Contd..3) 44

Products under Development by Companies, H1 2015 (Contd..4) 45

Products under Development by Companies, H1 2015 (Contd..5) 46

Products under Development by Companies, H1 2015 (Contd..6) 47

Products under Investigation by Universities/Institutes, H1 2015 48

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 50

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Absynth Biologics Limited, H1 2015 51

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Adenium Biotech ApS, H1 2015 52

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by AIMM Therapeutics B.V., H1 2015 53

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Alchemia Limited, H1 2015 54

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Allergan Plc, H1 2015 55

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by AlphaMab Co., Ltd, H1 2015 56

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Alvogen, Inc., H1 2015 57

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by AmpliPhi Biosciences Corporation, H1 2015 58

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by AnGes MG, Inc., H1 2015 59

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Aphios Corporation, H1 2015 60

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by AstraZeneca Plc, H1 2015 61

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 62

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Bharat Biotech International Limited, H1 2015 63

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by BioDiem Ltd, H1 2015 64

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by C3 Jian, Inc, H1 2015 65

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Cellceutix Corporation, H1 2015 66

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Cempra, Inc., H1 2015 67

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by ContraFect Corporation, H1 2015 68

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by CrystalGenomics, Inc., H1 2015 69

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by CSA Biotechnologies LLC , H1 2015 70

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Debiopharm International S.A., H1 2015 71

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by DesignMedix, Inc., H1 2015 72

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Destiny Pharma Limited, H1 2015 73

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Dong-A Socio Group, H1 2015 74

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Ensoltek Co., Ltd., H1 2015 75

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Excelimmune, Inc., H1 2015 76

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Galapagos NV, H1 2015 77

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by GangaGen Inc., H1 2015 78

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Helix BioMedix, Inc., H1 2015 79

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 80

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Immupharma Plc, H1 2015 81

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by ImmuVen, Inc., H1 2015 82

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by iNtRON Biotechnology Inc., H1 2015 83

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 84

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by LegoChem Biosciences, Inc, H1 2015 85

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Lytix Biopharma AS, H1 2015 86

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Madam Therapeutics B.V., H1 2015 87

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 88

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Merck & Co., Inc., H1 2015 89

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Microbiotix, Inc., H1 2015 90

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 91

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by MorphoSys AG, H1 2015 92

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Motif BioSciences, Inc., H1 2015 93

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 94

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by NanoBio Corporation, H1 2015 95

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 96

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Novabiotics Limited, H1 2015 97

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by NovaDigm Therapeutics, Inc., H1 2015 98

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015 99

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Novolytics Limited, H1 2015 100

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Oragenics, Inc., H1 2015 101

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Pepscan Presto BV, H1 2015 102

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Pfizer Inc., H1 2015 103

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by PharmaIN Corporation, H1 2015 104

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Phico Therapeutics Limited, H1 2015 105

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Pono Pharma, H1 2015 106

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Procarta Biosystems Ltd, H1 2015 107

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Redx Pharma Plc, H1 2015 108

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Sarepta Therapeutics, Inc., H1 2015 109

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Savara Inc., H1 2015 110

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 111

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015 112

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Soligenix, Inc., H1 2015 113

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Sorrento Therapeutics, Inc., H1 2015 114

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Syntiron LLC, H1 2015 115

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Taejoon Pharm Co., Ltd., H1 2015 116

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015 117

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 118

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by United Therapeutics Corporation, H1 2015 119

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Wintermute Biomedical LLC, H1 2015 120

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Wockhardt Limited, H1 2015 121

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by XBiotech USA, Inc., H1 2015 122

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 123

Assessment by Monotherapy Products, H1 2015 124

Assessment by Combination Products, H1 2015 125

Number of Products by Stage and Target, H1 2015 127

Number of Products by Stage and Mechanism of Action, H1 2015 130

Number of Products by Stage and Route of Administration, H1 2015 132

Number of Products by Stage and Molecule Type, H1 2015 134

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics-Recent Pipeline Updates, H1 2015 308

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects, H1 2015 356

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects (Contd..1), H1 2015 357

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects (Contd..2), H1 2015 358

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects (Contd..3), H1 2015 359

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects (Contd..4), H1 2015 360

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects (Contd..5), H1 2015 361

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Dormant Projects (Contd..6), H1 2015 362

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Discontinued Products, H1 2015 363

List of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2015 24

Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections-Comparative Analysis, H1 2015 25

Number of Products under Development by Companies, H1 2015 26

Number of Products under Investigation by Universities/Institutes, H1 2015 33

Comparative Analysis by Clinical Stage Development, H1 2015 38

Comparative Analysis by Early Stage Products, H1 2015 39

Assessment by Monotherapy Products, H1 2015 124

Number of Products by Top 10 Targets, H1 2015 126

Number of Products by Stage and Top 10 Targets, H1 2015 126

Number of Products by Top 10 Mechanism of Actions, H1 2015 129

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 129

Number of Products by Top 10 Routes of Administration, H1 2015 131

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 131

Number of Products by Top 10 Molecule Types, H1 2015 133

Number of Products by Stage and Top 10 Molecule Types, H1 2015 133

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Absynth Biologics Limited

Adenium Biotech ApS

AIMM Therapeutics B.V.

Alchemia Limited

Allergan Plc

AlphaMab Co., Ltd

Alvogen, Inc.

AmpliPhi Biosciences Corporation

AnGes MG, Inc.

Aphios Corporation

AstraZeneca Plc

Aurigene Discovery Technologies Limited

Bharat Biotech International Limited

BioDiem Ltd

C3 Jian, Inc

Cellceutix Corporation

Cempra, Inc.

ContraFect Corporation

CrystalGenomics, Inc.

CSA Biotechnologies LLC

Debiopharm International S.A.

DesignMedix, Inc.

Destiny Pharma Limited

Dong-A Socio Group

Ensoltek Co., Ltd.

Excelimmune, Inc.

Galapagos NV

GangaGen Inc.

Helix BioMedix, Inc.

Ildong Pharmaceutical Co., Ltd.

Immupharma Plc

ImmuVen, Inc.

iNtRON Biotechnology Inc.

Kyorin Pharmaceutical Co., Ltd.

LegoChem Biosciences, Inc

Lytix Biopharma AS

Madam Therapeutics B.V.

Melinta Therapeutics, Inc

Merck & Co., Inc.

Microbiotix, Inc.

MicuRx Pharmaceuticals, Inc.

MorphoSys AG

Motif BioSciences, Inc.

Nabriva Therapeutics AG

NanoBio Corporation

NovaBay Pharmaceuticals, Inc.

Novabiotics Limited

NovaDigm Therapeutics, Inc.

NovoBiotic Pharmaceuticals, LLC

Novolytics Limited

Oragenics, Inc.

Pepscan Presto BV

Pfizer Inc.

PharmaIN Corporation

Phico Therapeutics Limited

Pono Pharma

Procarta Biosystems Ltd

Redx Pharma Plc

Sarepta Therapeutics, Inc.

Savara Inc.

Sealife PHARMA GMBH

Sentinella Pharmaceuticals, Inc.

Soligenix, Inc.

Sorrento Therapeutics, Inc.

Syntiron LLC

Taejoon Pharm Co., Ltd.

TAXIS Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals Inc.

United Therapeutics Corporation

Wintermute Biomedical LLC

Wockhardt Limited

XBiotech USA, Inc.

Yungjin Pharm Ind. Co., Ltd.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutic Products under Development, Key Players in Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Overview, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com